SCHEMBL6799072

SCHEMBL6799072

CCOC(=O)c1cc2c(C(F)(F)F)cc(OCCO)cc2n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 4/20 0.38
MAOA P21397 1/20 0.37
HPGD P15428 2/20 0.37
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LDHA P00338 1/20 0.36
ALOX5 P09917 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 2/20 0.35
KMT2A Q03164 1/20 0.35
PGR P06401 1/20 0.35
AR P10275 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
HRH2 P25021 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799070 0.91 POLB (0.41) GAAPOLBKDM4EMAOAHPGD
SCHEMBL7877960 0.87 HPGD (0.45) GAAPOLBKDM4EMAOAHPGD
SCHEMBL6797980 0.87 POLB (0.38) GAAPOLBKDM4EMAOAHPGD
SCHEMBL6796884 0.87 AGER (0.40) GAAPOLBKDM4EMAOAHPGD
SCHEMBL6795763 0.86 POLB (0.38) GAAPOLBKDM4EMAOAHPGD
SCHEMBL6798270 0.83 PSEN1 (0.43) GAAPOLBKDM4EALDH1A1L3MBTL1
SCHEMBL6797332 0.83 POLB (0.34) GAAPOLBKDM4EMAOAHPGD
SCHEMBL7881981 0.83 SRD5A2 (0.45) GAAKDM4EMAOAHPGDALDH1A1
SCHEMBL7873290 0.82 DYRK1A (0.43) GAAPOLBKDM4ECYP2C19
SCHEMBL6798564 0.82 LDHA (0.36) GAAPOLBKDM4EMAOAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 GAA 292/4885POLB 1536/4885KDM4E 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.